1. Home
  2. SNDX vs NBHC Comparison

SNDX vs NBHC Comparison

Compare SNDX & NBHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • NBHC
  • Stock Information
  • Founded
  • SNDX 2005
  • NBHC 2009
  • Country
  • SNDX United States
  • NBHC United States
  • Employees
  • SNDX N/A
  • NBHC N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • NBHC Major Banks
  • Sector
  • SNDX Health Care
  • NBHC Finance
  • Exchange
  • SNDX Nasdaq
  • NBHC Nasdaq
  • Market Cap
  • SNDX 1.3B
  • NBHC 1.4B
  • IPO Year
  • SNDX 2016
  • NBHC 2012
  • Fundamental
  • Price
  • SNDX $19.91
  • NBHC $38.07
  • Analyst Decision
  • SNDX Strong Buy
  • NBHC Buy
  • Analyst Count
  • SNDX 12
  • NBHC 3
  • Target Price
  • SNDX $36.92
  • NBHC $44.33
  • AVG Volume (30 Days)
  • SNDX 3.0M
  • NBHC 291.4K
  • Earning Date
  • SNDX 11-03-2025
  • NBHC 10-21-2025
  • Dividend Yield
  • SNDX N/A
  • NBHC 3.29%
  • EPS Growth
  • SNDX N/A
  • NBHC N/A
  • EPS
  • SNDX N/A
  • NBHC 3.15
  • Revenue
  • SNDX $111,304,000.00
  • NBHC $405,867,000.00
  • Revenue This Year
  • SNDX $636.61
  • NBHC $8.48
  • Revenue Next Year
  • SNDX $114.95
  • NBHC $28.10
  • P/E Ratio
  • SNDX N/A
  • NBHC $11.96
  • Revenue Growth
  • SNDX 595.65
  • NBHC 1.03
  • 52 Week Low
  • SNDX $8.58
  • NBHC $32.83
  • 52 Week High
  • SNDX $20.08
  • NBHC $49.39
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 72.56
  • NBHC 60.22
  • Support Level
  • SNDX $16.75
  • NBHC $35.50
  • Resistance Level
  • SNDX $20.08
  • NBHC $38.26
  • Average True Range (ATR)
  • SNDX 1.23
  • NBHC 0.86
  • MACD
  • SNDX 0.40
  • NBHC 0.26
  • Stochastic Oscillator
  • SNDX 97.58
  • NBHC 93.12

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About NBHC National Bank Holdings Corporation

National Bank Holdings Corp is a bank holding company. It provides various banking products and financial services to commercial, business, and consumer clients in the United States. The company offers deposit products including checking accounts, savings accounts, money market accounts, and other deposit accounts, including fixed-rate and fixed-maturity time deposits. It also provides commercial and industrial loans and leases. In addition, it offers treasury management solutions comprising online and mobile banking, commercial credit cards, wire transfers, automated clearing house, and electronic bill payments.

Share on Social Networks: